Long-Term CARTITUDE-4 Update: ORR and DOR

Panelists discuss how data from the long-term update from CARTITUDE-4 reveal impressive overall response rates (ORRs) and duration of response (DOR) for ciltacabtagene autoleucel, reinforcing its effectiveness in treating lenalidomide-refractory multiple myeloma.

EP: 1.Impact of CAR T-Cell Therapy in R/R MM

EP: 2.Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy

EP: 3.Long-Term CARTITUDE-4 Study Update in MM

Now Viewing

EP: 4.Long-Term CARTITUDE-4 Update: ORR and DOR

EP: 5.Long-Term CARTITUDE 4: Rate of MRD Negativity

EP: 6.Safety Data from the Long-Term CARTITUDE-4 Update

EP: 7.Looking Ahead and Key Takeaways

Recent Videos